Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.
Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.
The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including HIV/AIDS, renal disease, cardiovascular disease, among others. In 2009, Concert’s first patents were granted by the USPTO.
**Source:** The company description above is sourced from the Wikipedia article Concert Pharmaceuticals (US) and protected under [CC-BY-SA](http://creativecommons.org/licenses/by-sa/3.0/ "CC-BY-SA") license. Company pages are neither affiliated with nor endorsed by the represented company.